Thrombin mediated cytotoxicity during cerebral ischemia
脑缺血期间凝血酶介导的细胞毒性
基本信息
- 批准号:9927678
- 负责人:
- 金额:$ 11.02万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-08-15 至 2020-09-12
- 项目状态:已结题
- 来源:
- 关键词:AddressAgonistAnimalsArgatrobanAstrocytesAttentionAwardBiological AssayBrainCaringCell CommunicationCellsCerebral IschemiaCerebrumClinical TrialsCollaborationsDataDoseElementsEndothelial CellsF2R geneFactor XaFundingGenesInjuryIschemiaKnockout MiceLentivirus VectorLiteratureMass Spectrum AnalysisMediatingMessenger RNAMicrofluidicsModelingMonitorMusNeuronal InjuryNeuronsOligodendrogliaPAR-1 ReceptorPeptide HydrolasesPeptidesPericytesPhasePlayProcessPropertyProteinsProteomicsProthrombinPublishingReactionResearchResearch PersonnelRoleSignal TransductionStimulusStrokeTamoxifenTechniquesTestingThrombinTrypsinWorkbasebehavioral outcomebrain cellconditional knockoutconditioningcytotoxicityexperimental studyimprovedin vivoinhibitor/antagonistinnovationinsightneuroprotectionneurovascular unitnovelparacrinepreconditioningreceptorresponseresponse to brain injuryresponse to injurystroke patienttool
项目摘要
We propose a novel and exciting hypothesis—based on literature and our own pilot data—that
neuronal injury stimulates astrocyte activation via thrombin and its receptor PAR-1, and the
resulting astrocyte response to injury yields transmissible paracrine protection of neurons.
Together, neurons, astroctyes, endothelial cells, pericytes, and oligodendroglia comprise the
neurovascular unit, or NVU. Data generated from the several aims will yield insights into the
mechanism for the well-documented phenomenon of pre-conditioning; will provide considerable
insights into the mechanisms of differential vulnerability to cerebral injury; and would likely yield
treatment options for stroke patients. To accomplish the aims, we are creating novel conditional
knock-out mice that will provide research tools to the broader research field. The previous
award, R01 NS075930, covered 8/15/2011 to 03/31/2015 and involved 4 aims. All proposed
work has been completed and published or under review. The data from our prior award has
already influenced stroke care significantly, in the form of two funded clinical trials. However, our
prior data could not fully explain the known differences among the elements of the NVU,
specifically, that astrocytes and endothelial cells tolerate ischemia better than neurons. What is
the mechanism of thrombin-mediated pre-conditioning, and can we relate that mechanism to
other forms of pre- and peri-conditioning? Why does the brain contain prothrombin mRNA and
protein and what purpose could be served by thrombin activation in brain? Could we derive
insights about the response of the brain to injury, and specifically explore the cell-subtype
interactions during injury among astrocytes, neurons, pericytes, oligodendroglia, and endothelial
cells? To answer these questions, and to address the central hypothesis of the present award
application, we added significant new models to our repertoire, and generated pilot data
speaking to the feasibility and novelty of the proposed new specific aims.
基于文献和我们自己的试验数据,我们提出了一个新颖而令人兴奋的假设,
神经元损伤通过凝血酶及其受体PAR-1刺激星形胶质细胞活化,
所产生的星形胶质细胞对损伤的反应产生神经元的可传递的旁分泌保护。
神经元、星形胶质细胞、内皮细胞、周细胞和少突胶质细胞共同构成了神经系统。
神经血管单位或NVU。从几个目标中产生的数据将有助于了解
预处理的良好记录现象的机制;将提供相当大的
深入了解脑损伤的不同脆弱性机制,并可能产生
中风患者的治疗选择。为了实现这些目标,我们正在创造新的条件,
基因敲除小鼠将为更广泛的研究领域提供研究工具。前一
裁决,R 01 NS 075930,涵盖2011年8月15日至2015年3月31日,涉及4个目标。所有拟议
工作已经完成并发表或正在审查中。我们之前的裁决数据
已经通过两项临床试验对中风护理产生了重大影响。但我们的
先前的数据不能完全解释NVU的元件之间的已知差异,
特别是星形胶质细胞和内皮细胞比神经元更能耐受缺血。是什么
凝血酶介导的预处理机制,我们能把这个机制与
其他形式的预适应和围适应为什么大脑含有凝血酶原mRNA,
蛋白质和什么目的可以通过凝血酶激活大脑?我们能否推导出
了解大脑对损伤的反应,特别是探索细胞亚型
损伤期间星形胶质细胞、神经元、周细胞、少突胶质细胞和内皮细胞之间的相互作用
细胞?为了回答这些问题,并解决本奖项的中心假设,
应用程序,我们添加了重要的新模型,我们的剧目,并产生试点数据
谈到拟议的新的具体目标的可行性和新奇。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Patrick D Lyden其他文献
Patrick D Lyden的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Patrick D Lyden', 18)}}的其他基金
ZZ-3K3A-301: A multicenter, randomized, placebo-controlled, double-blinded, Phase 3 study to evaluate the efficacy and safety of 3K3A-APC (RHAPSODY-2)
ZZ-3K3A-301:一项多中心、随机、安慰剂对照、双盲、3 期研究,旨在评估 3K3A-APC (RHAPSODY-2) 的有效性和安全性
- 批准号:
10305528 - 财政年份:2022
- 资助金额:
$ 11.02万 - 项目类别:
ZZ-3K3A-201: Safety evaluation of 3K3A-APC in ischemic stroke
ZZ-3K3A-201:3K3A-APC在缺血性中风中的安全性评价
- 批准号:
9095477 - 财政年份:2014
- 资助金额:
$ 11.02万 - 项目类别:
ZZ-3K3A-201: Safety evaluation of 3K3A-APC in ischemic stroke
ZZ-3K3A-201:3K3A-APC在缺血性中风中的安全性评价
- 批准号:
8760276 - 财政年份:2014
- 资助金额:
$ 11.02万 - 项目类别:
ZZ-3K3A-201: Safety evaluation of 3K3A-APC in ischemic stroke
ZZ-3K3A-201:3K3A-APC在缺血性中风中的安全性评价
- 批准号:
8880302 - 财政年份:2014
- 资助金额:
$ 11.02万 - 项目类别:
Thrombin mediated cytotoxicity during cerebral ischemia
脑缺血期间凝血酶介导的细胞毒性
- 批准号:
10327599 - 财政年份:2011
- 资助金额:
$ 11.02万 - 项目类别:
Thrombin Mediated Cytotoxicity during Cerebral Ischemia
脑缺血期间凝血酶介导的细胞毒性
- 批准号:
8318076 - 财政年份:2011
- 资助金额:
$ 11.02万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 11.02万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 11.02万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 11.02万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 11.02万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 11.02万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 11.02万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 11.02万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 11.02万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 11.02万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 11.02万 - 项目类别:
Grant-in-Aid for Scientific Research (C)